ILMN Stock Analysis — Illumina
Sector: Healthcare
AI Verdict
At 29.7x next year's earnings for 16.7% growth, you're paying a premium the numbers don't yet support unless Illumina's sequencing moat delivers a step-change in adoption.
Competitive Moat
Illumina dominates the DNA sequencing market through its proprietary sequencing-by-synthesis technology and a locked-in installed base of labs reliant on its instruments and consumables. This recurring consumables revenue and high switching costs make its position defensible against new entrants.
Summary
Illumina's forward P/E of 29.7x and a 1-year return of 96.81% put it back in the spotlight as investors bet on a rebound in genomics.
Where It Stands
With a 1-year return of 96.81%, an RSI of 66.3 (elevated), and a forward P/E of 29.7x versus the healthcare median of 22x, the stock is running hot and commands a premium.
Key Metrics
- RSI: 66.3 — Near Overbought
- Trailing P/E: 34.6x
- Forward P/E: 29.7x
- PEG Ratio: 2.14
- Earnings Growth: +0.2%
- Revenue Growth: +0.0%
- Market Cap: $28.9B
- 1-Year Return: 96.81%
- 52-Week High: $196.66
- 52-Week Low: $88.00
Analyst Consensus
17 Buy · 8 Hold · 3 Sell (28 analysts)
Bull Case
Forward EPS growth of 16.7% and a forward P/E of 29.7x mean investors are paying up for double-digit earnings expansion backed by Illumina's entrenched technology.
Bear Case
If the P/E compresses from 29.7x to the healthcare sector median of 22x, the stock would lose about 26% even if earnings meet expectations.
Catalyst to Watch
Watch for new product launches or regulatory updates that could accelerate adoption or, conversely, disrupt the installed base.